Unfortunately, the discovery that many forms of cancer can harbour somatic mutations resulting in overexpression of NRF2 and subsequent tumour resistance makes the recommendation of pharmacological NRF2 stimulators to alleviate off-target effects of cardiotoxic drugs, notably the anthracycline class of chemotherapeutics, difficult. The gene discussed is NFE2L2; the disease is cancer.